ADC Landscape
BioNTech (DualityBio)
HER2 · Breast, endometrial cancer
Phase 3Antibody–Drug Conjugates
Target
HER2
Payload
Topo-I (P1003)
Payload class
Topo-I inhibitor
Linker
Cleavable
Indication
Breast, endometrial cancer
Phase
Phase 3
Partner
DualityBio
Overview
BioNTech's pivot beyond mRNA into ADCs via China's DualityBio. A HER2 DXd-class follower betting on combination with its immunotherapy pipeline.
Technology
BioNTech (DualityBio) works in Antibody–Drug Conjugates — A guided missile: an antibody that flies a chemo warhead straight to the tumor.
Read the Antibody–Drug Conjugates brief →Related companies
Daiichi Sankyo
HER2
Gilead
TROP2
AstraZeneca / Daiichi
TROP2
Pfizer (Seagen)
CD30
Pfizer (Seagen)
Nectin-4
Pfizer (Seagen)
Tissue Factor
Company website / source ↗ Open the interactive map →
◢ Boom-cycle briefing
Get ahead of the next biotech boom.
New companies, stage changes, deal alerts and fresh tech briefs — one sharp email when the map moves.
Curated biotech intelligence, compiled for orientation — not investment advice. Company stages, deals and figures move fast; verify against ClinicalTrials.gov, company filings and primary sources before acting.